From the Children's Hospital Colorado and University of Colorado School of Medicine (J.A.J.), Aurora; Department of Psychology (B.P.K.-T.), University of Wisconsin-Milwaukee; Murdoch Children's Research Institute and Department of Pediatrics (J.M.P., K.H.), University of Melbourne, Australia; Pediatric Oncology Branch (P.L.W., S.M., M.A.T.-T.), National Cancer Institute, Bethesda, MD; Department of Communication Sciences and Disorders (H.L.T.), California State University, Sacramento; University of Cincinnati Medical Center (P.d.B.), OH; Boston Children's Hospital (N.U.), MA; Children's National Hospital, Gilbert NF Institute (A.d.C., K.K.H., K.S.W.), Washington, DC; Children's Tumor Foundation (M.H.), New York, NY; The George Washington School of Medicine (K.K.H., K.S.W.), Washington, DC; Children's Hospital Los Angeles (T.R.), CA; and Leidos Biomedical Research, Inc. (M.A.T.-T.), Frederick, MD.
Neurology. 2021 Aug 17;97(7 Suppl 1):S73-S80. doi: 10.1212/WNL.0000000000012422. Epub 2021 Jul 6.
To review parent-report social skills measures to identify and recommend consensus outcomes for use in clinical trials of social deficit in children and adolescents (ages 6-18 years) with neurofibromatosis type 1 (NF1).
Searches were conducted via PubMed and ClinicalTrials.gov to identity social skills outcome measures with English language versions used in clinical trials in the past 5 years with populations with known social skills deficits, including attention-deficit/hyperactivity disorder and autism spectrum disorder (ASD). Measures were rated by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Neurocognitive Committee on patient characteristics, use in published studies, domains assessed, availability of standard scores, psychometric properties, and feasibility to determine their appropriateness for use in NF1 clinical trials.
Two measures were ultimately recommended by the committee: the Social Responsiveness Scale-2 (SRS-2) and the Social Skills Improvement System-Rating Scale (SSIS-RS).
Each of the 2 measures assesses different aspects of social functioning. The SSIS-RS is appropriate for studies focused on broader social functioning; the SRS-2 is best for studies targeting problematic social behaviors associated with ASD. Researchers will need to consider the goals of their study when choosing a measure, and specific recommendations for their use are provided.
回顾家长报告的社交技能评估方法，以确定并推荐共识结果，用于在患有 1 型神经纤维瘤病（NF1）的儿童和青少年（6-18 岁）的社交缺陷临床试验中使用。
通过 PubMed 和 ClinicalTrials.gov 进行检索，以确定过去 5 年内用于具有已知社交技能缺陷的人群（包括注意力缺陷/多动障碍和自闭症谱系障碍（ASD））临床试验的英语社交技能评估方法。评估方法由神经纤维瘤病和雪旺细胞瘤（REiNS）神经认知委员会根据患者特征、在已发表研究中的使用情况、评估的领域、标准分数的可用性、心理测量特性和可行性进行评估，以确定其在 NF1 临床试验中的适用性。
委员会最终推荐了两种评估方法：社交反应量表-2（SRS-2）和社交技能改善系统评定量表（SSIS-RS）。
这两种评估方法都评估了社交功能的不同方面。SSIS-RS 适用于关注更广泛社交功能的研究；SRS-2 最适合针对与 ASD 相关的有问题的社交行为的研究。研究人员在选择评估方法时需要考虑其研究目标，并提供了具体的使用建议。
